BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 27825460)

  • 21. The epidemiology of Waldenström macroglobulinemia.
    McMaster ML
    Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgM monoclonal gammopathy/Waldenström's macroglobulinemia: a morphological and immunophenotypic study of the bone marrow.
    Feiner HD; Rizk CC; Finfer MD; Bannan M; Gottesman SR; Chuba JV; Amorosi E
    Mod Pathol; 1990 May; 3(3):348-56. PubMed ID: 2114024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the bone marrow in Waldenstrom macroglobulinemia.
    Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
    Naderi N; Yang DT
    Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
    Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiogenesis in Waldenström's macroglobulinemia.
    Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The malignant clone in Waldenstrom's macroglobulinemia.
    Kriangkum J; Taylor BJ; Mant MJ; Treon SP; Belch AR; Pilarski LM
    Semin Oncol; 2003 Apr; 30(2):132-5. PubMed ID: 12720122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
    San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
    Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing diagnostic criteria in Waldenstrom's macroglobulinemia.
    Owen RG
    Semin Oncol; 2003 Apr; 30(2):196-200. PubMed ID: 12720135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
    Pangalis GA; Kyrtsonis MC; Kontopidou FN; Siakantaris MP; Dimopoulou MN; Vassilakopoulos TP; Tzenou T; Kokoris S; Dimitriadou E; Kalpadakis C; Tsalimalma K; Tsaftaridis P; Panayiotidis P; Angelopoulou MK
    Clin Lymphoma; 2005 Mar; 5(4):235-40. PubMed ID: 15794855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Waldenström's macroglobulinemia: a clinicopathologic study of 22 cases.
    Andriko JA; Aguilera NS; Chu WS; Nandedkar MA; Cotelingam JD
    Cancer; 1997 Nov; 80(10):1926-35. PubMed ID: 9366295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual evolution of Waldenström's macroglobulinemia into osteolytic myeloma.
    Jondeau K; Alterescu R; Franc B; Davi F; Massé JM; Boukour S; Le Parc JM; Cramer EM
    Eur J Haematol; 2006 Jul; 77(1):74-9. PubMed ID: 16827885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Wang JJ; Jing HM; Shen HW; Xu JS; Li M; Gao ZF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1494-8. PubMed ID: 21176358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of plasma cells in Waldenström macroglobulinaemia.
    El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
    Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
    Neparidze N; Dhodapkar MV
    Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Papasotiriou I; Fotiou D; Migkou M; Roussou M; Kanellias N; Ziogas D; Dialoupi I; Eleutherakis Papaiakovou E; Kastritis E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):23-28. PubMed ID: 30224328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence and expression analyses of mu and delta transcripts in patients with Waldenström's macroglobulinemia.
    Shiokawa S; Suehiro Y; Uike N; Muta K; Nishimura J
    Am J Hematol; 2001 Nov; 68(3):139-43. PubMed ID: 11754393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
    Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
    N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
    Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
    Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.